Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.

被引：0
|
作者：
Kunz, Pamela L.
Ferone, Diego
Halperin, Daniel M.
Myrehaug, Sten
Herrmann, Ken
Pavel, Marianne
Chasen, Beth
Capdevila, Jaume
Tafuto, Salvatore
Oh, Do-Youn
Yoo, Changhoon
Falk, Stephen
Halfdanarson, Thorvardur Ragnar
Folitar, Ilya
Zhang, Yufen
de Herder, Wouter W.
Singh, Simron
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] IRCCS Policlin San Martino, Genoa, Italy
[3] Univ Genoa, Genoa, Italy
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Univ Toronto, Toronto, ON, Canada
[6] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[7] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[8] Friedrich Alexander Univ Erlangen Nurnberg, Uniklinikum Erlangen, Erlangen, Germany
[9] Vall Hebron Univ Hosp, Barcelona, Spain
[10] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[11] Ist Nazl Tumori IRCCS, Oncol Clin & Sperimentale Sarcomi & Tumori Rari, Naples, Italy
[12] Seoul Natl Univ, Coll Med, Grad Sch, Seoul Natl Univ Hosp,Canc Res Inst, Seoul, South Korea
[13] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[14] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol, England
[15] Mayo Clin, Rochester, MN USA
[16] Novartis Pharma AG, Basel, Switzerland
[17] Novartis Pharmaceut, E Hanover, NJ USA
[18] Erasmus MC, Rotterdam, Netherlands
[19] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4131
引用
收藏
页数：1
相关论文
共 18 条
  • [1] [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study
    Singh, Simron
    Halperin, Daniel M.
    Myrehaug, Sten
    Herrmann, Ken
    Pavel, Marianne
    Kunz, Pamela L.
    Chasen, Beth
    Capdevila, Jaume
    Tafuto, Salvatore
    Oh, Do-Youn
    Yoo, Changhoon
    Falk, Stephen
    Halfdanarson, Thorvardur Ragnar
    Folitar, Ilya
    Zhang, Yufen
    Santoro, Paola
    Aimone, Paola
    de Herder, Wouter W.
    Ferone, Diego
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA588 - LBA588
  • [2] [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomised NETTER-2 study
    de Herder, W. W.
    Halperin, D.
    Myrehaug, S.
    Herrmann, K.
    Pavel, M.
    Kunz, P. L.
    Chasen, B.
    Capdevila, J.
    Tafuto, S.
    Oh, D. Y.
    Yoo, C.
    Falk, S.
    Halfdanarson, T.
    Folitar, I
    Zhang, Y.
    Santoro, P.
    Aimone, P.
    Ferone, D.
    Singh, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 203 - 203
  • [3] First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study
    Singh, S.
    Halperin, D.
    Myrehaug, S.
    Herrmann, K.
    Pavel, M. E.
    Kunz, P. L.
    Chasen, B.
    Capdevila, J.
    Tafuto, S.
    Oh, D-Y.
    Yoo, C.
    Falk, S.
    Halfdanarson, T. R.
    Folitar, I.
    Zhang, Y.
    de Herder, W. W.
    Ferone, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S92 - S93
  • [4] [177Lu]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study
    Singh, Simron
    Pavel, Marianne
    Kunz, Pamela L.
    de Herder, Wouter
    Herrmann, Ken
    D'Amelio, Anthony M., Jr.
    Santoro, Paola
    Folitar, Ilya
    Ferone, Diego
    PANCREAS, 2022, 51 (03) : E58 - E58
  • [5] [177LU]LU-DOTA-TATE AS FIRST-LINE THERAPY FOR PATIENTS WITH GRADE 2 AND 3 ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS (GEP-NETS): THE NETTER-2 STUDY
    Myrehaug, Sten
    Singh, Simron
    Pavel, Marianne
    Kunz, Pamela
    de Herder, Wouter
    Herrmann, Ken
    D'Amelio, Anthony, Jr.
    Santoro, Paola
    Folitar, Ilya
    Ferone, Diego
    RADIOTHERAPY AND ONCOLOGY, 2022, 174 : S40 - S41
  • [6] [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
    Singh, Simron
    Halperin, Daniel
    Myrehaug, Sten
    Herrmann, Ken
    Pavel, Marianne
    Kunz, Pamela L.
    Chasen, Beth
    Tafuto, Salvatore
    Lastoria, Secondo
    Capdevila, Jaume
    Garcia-Burillo, Amparo
    Oh, Do-Youn
    Yoo, Changhoon
    Halfdanarson, Thorvardur R.
    Falk, Stephen
    Folitar, Ilya
    Zhang, Yufen
    Aimone, Paola
    de Herder, Wouter W.
    Ferone, Diego
    LANCET, 2024, 403 (10446): : 2807 - 2817
  • [7] Compose: Pivotal Phase III Trial of 177Lu-Edotreotide Versus Best Standard of Care in Well-Differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuroendocrine Tumors
    Halfdanarson, Thorvardur R.
    Reidy, Diane
    Vijayvergia, Namrata
    Halperin, Daniel
    Goldstein, Grace
    Kong, Grace
    Michael, Michael
    Leyden, Simone
    Grozinsky-Glasberg, Simona
    Sorbye, Halfdan
    Oberg, Kjell
    Thevenet, Thomas
    Herrmann, Martina Christine
    PANCREAS, 2022, 51 (03) : E44 - E44
  • [8] COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
    Halfdanarson, T. R.
    Halperin, D.
    Reidy-Lagunes, D.
    Kong, G.
    Mailman, J.
    Herrmann, K.
    Rajaskanthan, R. Sri
    Leyden, S.
    Capdevila Castillon, J.
    Sierras, C.
    Harris, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S960 - S960
  • [9] Analysis of Somatostatin Receptor Imaging Modalities and the Relationship Between Tumor Uptake and Treatment Response to [177Lu]Lu-DOTA-TATE in Patients from the Randomized Phase 3 NETTER-2 study
    Herrmann, Ken
    Ferone, Diego
    Halperin, Daniel M.
    Myrehaug, Sten
    Pavel, Marianne
    Kunz, Pamela
    Chasen, Beth
    Capdevila, Jaume
    Tafuto, Salvatore
    Oh, Do-Youn
    Yoo, Changhoon
    Falk, Stephen
    Halfdanarson, Thorvardur R.
    Folitar, Ilya
    Zhang, Yufen
    de Herder, Wouter
    Singh, Simron
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [10] Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial (vol 37, e70018, 2025)
    不详
    JOURNAL OF NEUROENDOCRINOLOGY, 2025,
12